07 September 2015 : Review article
Comparison of Effects of Thiazolidinediones and Metformin on the HOMA Index in Type 2 Diabetics: A Meta-Analysis
Rui WangABCDEF, Ri-bao WeiAG, Na WangB, Meng-jie HuangBC, Yue YangBD, Yue XingB, Zi-cheng WangBDOI: 10.12659/MSRev.895147
Med Sci Rev 2015; 2:81-91
Abstract
Background: Insulin resistance(IR) precedes and plays a pivotal role in type 2 diabetes and occurs early in the natural history of the disease. This investigation compared the efficacy of thiazolidinediones(TZDs) and metformin(MET) in the effect of insulin resistance(IR) as assessed using the homeostasis model assessment(HOMA) index in drug-naive type 2 diabetic patients. Material and Methods: We searched the MEDLINE, EMBASE, and Cochrane Library databases to identify studies published before February 2015 that investigated the use of TZDs and MET to determine the effect on the HOMA index in drug-naive type 2 diabetics. Parameters on IR, HbA1c, BMI and waist circumference were collected. Review Manager 5.3 and Stata 12.0 were used to perform the meta-analysis. Fixed and random effects models were applied to various aspects of the meta-analysis, which assessed the therapeutic effects of the two types of drug using the HOMA index in type 2 diabetics. The meta-analysis included nine randomized controlled short trials (12~18 weeks). Results: Participants comparisons before and after treatment with TZDs and MET revealed that TZDs and MET treatments could improve HOMA index and lower FPG, FPI, HbA1c in drug-naive type 2 diabetics with lifestyle intervention. No significant differences in the therapeutic effects of these two types of drug on HOMA index, HbA1c, BMI and waist circumference were observed. Conclusions: On the basis of life intervention, either TZDs or MET might be a good choice in drug-naive type 2 diabetics.
Keywords: Diabetes Mellitus, Type 2, Insulin Resistance, Thiazolidinediones
Editorial
01 September 2023 : Editorial
Editorial: A Rapid Global Increase in COVID-19 is Due to the Emergence of the EG.5 (Eris) Subvariant of Omicron SARS-CoV-2DOI: 10.12659/MSM.942244
Med Sci Monit 2023; 29:e942244
In Press
28 Sep 2023 : Clinical Research
Trends in Hospitalization Duration for Rare Diseases: A Retrospective Analysis of Sarcoidosis, Still's Dise...Med Sci Monit In Press; DOI: 10.12659/MSM.941536
27 Sep 2023 : Laboratory Research
Enhanced Proliferation and Adhesion Marker Gene Expression in Fibroblast Cells: Evaluating the Efficacy of ...Med Sci Monit In Press; DOI: 10.12659/MSM.941641
26 Sep 2023 : Clinical Research
Hypothalamic Injury and Clinical Outcomes in Patients with Post-Traumatic Hyponatremia: A Diffusion Tensor ...Med Sci Monit In Press; DOI: 10.12659/MSM.942397
26 Sep 2023 : Clinical Research
Psychometric Properties of the Polish Version of the FACIT-Sp-12: Assessing Spiritual Well-Being Among Pati...Med Sci Monit In Press; DOI: 10.12659/MSM.941769
Most Viewed Current Articles
13 Nov 2021 : Clinical Research
Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...DOI :10.12659/MSM.932788
Med Sci Monit 2021; 27:e932788
30 Dec 2021 : Clinical Research
Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...DOI :10.12659/MSM.935379
Med Sci Monit 2021; 27:e935379
14 Dec 2022 : Clinical Research
Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase LevelsDOI :10.12659/MSM.937990
Med Sci Monit 2022; 28:e937990
08 Mar 2022 : Review article
A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...DOI :10.12659/MSM.936292
Med Sci Monit 2022; 28:e936292